Cell-free microRNAs as Non-invasive Diagnostic and Prognostic Bio- markers in Pancreatic Cancer
- PMID: 32581645
- PMCID: PMC7290054
- DOI: 10.2174/1389202921666191217095017
Cell-free microRNAs as Non-invasive Diagnostic and Prognostic Bio- markers in Pancreatic Cancer
Abstract
Pancreatic cancer (PaC) is one of the most lethal cancers, with an increasing global incidence rate. Unfavorable prognosis largely results from associated difficulties in early diagnosis and the absence of prognostic and predictive biomarkers that would enable an individualized therapeutic approach. In fact, PaC prognosis has not improved for years, even though much efforts and resources have been devoted to PaC research, and the multimodal management of PaC patients has been used in clinical practice. It is thus imperative to develop optimal biomarkers, which would increase diagnostic precision and improve the post-diagnostic management of PaC patients. Current trends in biomarker research envisage the unique opportunity of cell-free microRNAs (miRNAs) present in circulation to become a convenient, non-invasive tool for accurate diagnosis, prognosis and prediction of response to treatment. This review analyzes studies focused on cell-free miRNAs in PaC. The studies provide solid evidence that miRNAs are detectable in serum, blood plasma, saliva, urine, and stool, and that they present easy-to-acquire biomarkers with strong diagnostic, prognostic and predictive potential.
Keywords: Cell-free microRNA; diagnosis; non-invasive biomarker; pancreatic cancer; prediction; prognosis.
© 2019 Bentham Science Publishers.
Similar articles
-
Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer.Clin Chem. 2012 Mar;58(3):610-8. doi: 10.1373/clinchem.2011.172767. Epub 2011 Dec 22. Clin Chem. 2012. PMID: 22194634
-
Cell-free microRNAs as diagnostic, prognostic, and predictive biomarkers for lung cancer.Genes Chromosomes Cancer. 2013 Apr;52(4):356-69. doi: 10.1002/gcc.22032. Epub 2012 Dec 10. Genes Chromosomes Cancer. 2013. PMID: 23404859 Review.
-
Altered profile of serum microRNAs in pancreatic cancer-associated new-onset diabetes mellitus.J Diabetes. 2016 May;8(3):422-33. doi: 10.1111/1753-0407.12313. Epub 2015 Sep 15. J Diabetes. 2016. PMID: 25991015
-
Cell-free miRNAs as non-invasive biomarkers in breast cancer: Significance in early diagnosis and metastasis prediction.Life Sci. 2020 Apr 1;246:117417. doi: 10.1016/j.lfs.2020.117417. Epub 2020 Feb 7. Life Sci. 2020. PMID: 32044304 Review.
-
Updates and current challenges in microRNA research for personalized medicine in ovarian cancer.Expert Opin Biol Ther. 2017 Aug;17(8):927-943. doi: 10.1080/14712598.2017.1340935. Epub 2017 Jun 22. Expert Opin Biol Ther. 2017. PMID: 28641048 Review.
Cited by
-
Circulating Biomarkers for Cancer Detection: Could Salivary microRNAs Be an Opportunity for Ovarian Cancer Diagnostics?Biomedicines. 2023 Feb 21;11(3):652. doi: 10.3390/biomedicines11030652. Biomedicines. 2023. PMID: 36979630 Free PMC article. Review.
-
Application of Mass Spectrometry in Pancreatic Cancer Translational Research.Front Oncol. 2021 Oct 11;11:667427. doi: 10.3389/fonc.2021.667427. eCollection 2021. Front Oncol. 2021. PMID: 34707986 Free PMC article. Review.
-
Recent Insights into Therapy Resistance in Osteosarcoma.Cancers (Basel). 2020 Dec 30;13(1):83. doi: 10.3390/cancers13010083. Cancers (Basel). 2020. PMID: 33396725 Free PMC article. Review.
-
Mechanism underlying the regulation of lncRNA ACTA2-AS1 on CXCL2 by absorbing miRNA-532-5p as ceRNA in the development of ovarian cancer.Int J Clin Exp Pathol. 2021 May 15;14(5):596-607. eCollection 2021. Int J Clin Exp Pathol. 2021. PMID: 34093945 Free PMC article.
-
The Impact of Biomarkers in Pancreatic Ductal Adenocarcinoma on Diagnosis, Surveillance and Therapy.Cancers (Basel). 2022 Jan 3;14(1):217. doi: 10.3390/cancers14010217. Cancers (Basel). 2022. PMID: 35008381 Free PMC article. Review.
References
-
- Ferlay J., Soerjomataram I., Dikshit R., Eser S., Mathers C., Rebelo M., Parkin D.M., Forman D., Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer. 2015;136(5):E359–E386. [http://dx.doi.org/10.1002/ijc.29210]. [PMID: 25220842]. - PubMed
-
- Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2018. CA Cancer J. Clin. 2018;68(1):7–30. [http://dx.doi.org/10.3322/caac.21442]. [PMID: 29313949]. - PubMed
-
- Wong M.C.S., Jiang J.Y., Liang M., Fang Y., Yeung M.S., Sung J.J.Y. Global temporal patterns of pancreatic cancer and association with socioeconomic development. Sci. Rep. 2017;7(1):3165. [http://dx.doi.org/10.1038/s41598-017-02997-2]. [PMID: 28600530]. - PMC - PubMed
-
- Vincent A., Herman J., Schulick R., Hruban R.H., Goggins M. Pancreatic cancer. Lancet. 2011;378(9791):607–620. [http://dx.doi.org/10.1016/S0140-6736(10)62307-0]. [PMID: 21620466]. - PMC - PubMed
-
- Rhim A.D., Mirek E.T., Aiello N.M., Maitra A., Bailey J.M., McAllister F., Reichert M., Beatty G.L., Rustgi A.K., Vonderheide R.H., Leach S.D., Stanger B.Z. EMT and dissemination precede pancreatic tumor formation. Cell. 2012;148(1-2):349–361. [http://dx.doi.org/10.1016/j.cell.2011.11.025]. [PMID: 22265420]. - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources